Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

Dziadziuszko, Rafal; Smit, Egbert F; Dafni, Urania; Wolf, Juergen; Wasąg, Bartosz; Biernat, Wojciech; Finn, Stephen P; Kammler, Roswitha; Tsourti, Zoi; Rabaglio, Manuela; Ruepp, Barbara; Roschitzki-Voser, Heidi; Stahel, Rolf A; Felip, Enriqueta; Peters, Solange (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of thoracic oncology, 14(6), pp. 1086-1094. Elsevier 10.1016/j.jtho.2019.02.017

Full text not available from this repository. (Request a copy)

INTRODUCTION Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. Activity of various biologically distinct HER2 inhibitors, including the pan-HER inhibitor afatinib, has been reported in several retrospective trials or small series in advanced pretreated NSCLC with HER2 mutations. We report the first prospective evaluation of afatinib for the treatment of this molecularly defined entity. METHODS NICHE, a single-arm phase II trial using a two-stage Simon's design, explored the potential of afatinib to control disease in pretreated patients with advanced NSCLC harboring HER2 exon 20 mutations. A total of 13 patients entered the trial and were treated with afatinib 40 mg/day until tumor progression or lack of tolerability. RESULTS The first-stage stopping boundary was crossed when five of nine patients did not achieve disease control at 12 weeks. The accrual into the trial was stopped with total 13 patients enrolled, with 7 (53.8%) achieving disease control at 12 weeks. Except for 1 patient with early death, progression was documented for all patients, with median progression-free survival of 15.9 weeks (95% confidence interval: 6.0-35.4), and median overall survival of 56.0 weeks (95% confidence interval: 16.3- upper limit not estimable). The toxicity profile was in the expected range. CONCLUSIONS Afatinib did not show the expected potential for disease control in NSCLC. However, more than half of the patients in the full cohort achieved disease control at 12 weeks.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Rabaglio, Manuela

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1556-1380

Publisher:

Elsevier

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

21 Nov 2019 13:46

Last Modified:

21 Nov 2019 13:46

Publisher DOI:

10.1016/j.jtho.2019.02.017

PubMed ID:

30825613

Uncontrolled Keywords:

Afatinib NSCLC erb-b2 receptor tyrosine kinase 2 (HER2) mutations

URI:

https://boris.unibe.ch/id/eprint/134972

Actions (login required)

Edit item Edit item
Provide Feedback